Welcome to our dedicated page for Fusion Pharmaceuticals Common Shares news (Ticker: FUSN), a resource for investors and traders seeking the latest updates and insights on Fusion Pharmaceuticals Common Shares stock.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) is a clinical-stage oncology company based in Hamilton, Ontario, Canada, and Boston, focusing on the development of next-generation radioconjugates (RCs) for precision cancer treatments. The company specializes in targeted alpha therapy (TAT), leveraging their unique expertise in linking alpha particle-emitting isotopes to targeting molecules to create highly effective therapeutics.
Fusion’s lead program, FPI-2265, is designed specifically for metastatic castration-resistant prostate cancer (mCRPC). This innovative treatment targets the prostate-specific membrane antigen (PSMA) and is currently undergoing a Phase 2 clinical trial. FPI-2265 aims to improve patient outcomes by delivering a potent radioactive payload directly to cancer cells, minimizing damage to healthy tissues. The recent Phase 2 TATCIST trial results, presented at the AACR Annual Meeting 2024, demonstrated promising clinical activity and safety, with meaningful improvements in secondary endpoints for mCRPC patients.
Fusion’s pipeline includes several other promising candidates, such as FPI-1434, targeting the insulin growth factor 1 receptor (IGF1R), FPI-2059, targeting the neurotensin receptor 1 (NTSR1), and FPI-2068, a bispecific IgG-based RC targeting EGFR-cMET.
The recent acquisition of Fusion by AstraZeneca marks a significant milestone. AstraZeneca will acquire all of Fusion’s outstanding shares for $21.00 per share in cash, plus a non-transferable contingent value right of $3.00 per share, subject to achieving specific regulatory milestones. This acquisition, valued at approximately $2.4 billion, underscores Fusion's pivotal role in pioneering RCs and enhancing AstraZeneca's oncology portfolio.
Fusion operates a state-of-the-art Good Manufacturing Practice (GMP) compliant facility, ensuring the production of clinical doses for its expanding pipeline. The company has strategic actinium supply agreements with Niowave, Inc., and BWXT Medical to meet the growing demand for their therapies.
With a robust pipeline, strategic partnerships, and a strong balance sheet, Fusion is well-positioned to advance their mission of transforming cancer treatment through innovative alpha-emitting radioconjugates.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced the grant of stock option awards for 60,000 shares to a new employee, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $7.79, matching the closing stock price on March 28, 2022. Each option has a ten-year term and vests over four years. The company focuses on developing next-generation radiopharmaceuticals, with their lead program, FPI-1434, currently in Phase 1 clinical trials. Collaborations with AstraZeneca and Merck enhance their pipeline's potential.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced on March 24, 2022, that its Board of Directors granted stock options to purchase 25,800 shares of common stock to two new employees. The options have an exercise price of $7.50 per share, matching the closing stock price on March 21, 2022. These options vest over four years, beginning with 25% on the first anniversary. Fusion focuses on developing next-generation radiopharmaceuticals, with ongoing Phase 1 trials for its lead program, FPI-1434, and collaborations with AstraZeneca and Merck for targeted therapies.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) reported financial results for Q4 2021, showing a net loss of $17.2 million, or $0.40 per share, an increase from the previous year's loss of $13.4 million. As of December 31, 2021, the company had $220.8 million in cash and investments, sufficient to fund operations through 2023.
The company advances its first targeted alpha therapy candidate in collaboration with AstraZeneca and is expanding its pipeline into peptide-based radiopharmaceuticals. Phase 1 data for candidate FPI-1434 is expected in the second half of 2022.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced on March 9, 2022, that its Board of Directors granted stock option awards for 101,200 shares of common stock to two new employees, outside of the 2020 Stock Option and Incentive Plan. The exercise price is set at $7.00 per share, equal to the March 7 closing price. Each option has a ten-year term and vests over four years. Fusion specializes in developing radiopharmaceuticals for oncology, with ongoing clinical trials for its lead product, FPI-1434, among others, and collaborations with AstraZeneca and Merck.
Fusion Pharmaceuticals (Nasdaq: FUSN) announced its participation in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. CEO John Valliant, Ph.D. will represent the company. A webcast of the event will be available on their website, with a replay accessible for about 30 days. Fusion is focused on developing next-generation radiopharmaceuticals as precision medicines, with ongoing clinical trials and collaborations with major partners like AstraZeneca and Merck.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has granted stock options to purchase 12,600 shares of common stock to a new employee, as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.07, matching the company's closing stock price on February 7, 2022. These options feature a ten-year term and vest over four years. Fusion focuses on next-generation radiopharmaceuticals, with a pipeline including FPI-1434 in Phase 1 trials and collaborations with AstraZeneca and Merck for targeted therapies.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced its participation in the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 2:00 p.m. ET. CEO John Valliant, Ph.D., will present on behalf of the company. A webcast of the event will be available on the company's website, with a replay accessible for 90 days post-presentation. Fusion focuses on developing precision medicines through next-generation radiopharmaceuticals, with its lead program, FPI-1434, currently in Phase 1 clinical trials, and collaborations with AstraZeneca and Merck.
Fusion Pharmaceuticals Inc. granted stock option awards for 119,000 shares to a new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.60 per share, equal to the closing price on January 14, 2022. Each option has a ten-year term and vesting schedule, with 25% vesting after one year and the remaining vesting monthly over three years. Fusion focuses on developing radiopharmaceuticals as precision medicines, with its lead program in Phase 1 clinical trials.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company, announced a strategic research collaboration with Pepscan Therapeutics B.V. to discover novel peptide-based radiopharmaceuticals targeting solid tumors. This collaboration grants Fusion global rights to develop and commercialize any peptides discovered. Fusion aims to leverage its internal capabilities and Pepscan's proprietary platform for peptide discovery, enhancing its pipeline of targeted alpha therapies (TATs). Notably, Fusion's lead program, FPI-1434, is currently in Phase 1 clinical trials targeting the insulin-like growth factor 1 receptor.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) has entered a strategic research collaboration with 48 Hour Discovery Inc. to develop novel peptide-based radiopharmaceuticals targeting various solid tumors. This partnership grants Fusion global rights to commercialize any resulting peptides. CEO John Valliant emphasized that this collaboration enhances their capabilities in targeted alpha therapies (TATs), leveraging their existing drug programs and internal research capabilities. Fusion's lead program, FPI-1434, is in Phase 1 trials, underscoring their commitment to advancing oncology treatments.
FAQ
What is the current stock price of Fusion Pharmaceuticals Common Shares (FUSN)?
What is the market cap of Fusion Pharmaceuticals Common Shares (FUSN)?
What does Fusion Pharmaceuticals Inc. specialize in?
What is Fusion's lead program?
What recent achievement has Fusion Pharmaceuticals accomplished?
What is the significance of the acquisition by AstraZeneca?
Which other products are in Fusion Pharmaceuticals' pipeline?
What was revealed in the Phase 2 TATCIST trial of FPI-2265?
Where is Fusion Pharmaceuticals headquartered?
What type of facility does Fusion operate for manufacturing?
Who are Fusion's strategic supply partners?
What financial terms were involved in AstraZeneca's acquisition of Fusion?
